Engineered immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT07156045
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new cell therapy called anti-PSMA CAR NK cells in 10 people with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that no longer responds to hormone therapy. The treatment uses immune cells engineered to target a protein called PSMA on cancer cells. The main goal is to check safety and side effects, with early signs of effectiveness also being measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-PSMA CAR NK cells
What this could lead to
If it works, this could point toward a new cell therapy for advanced prostate cancer that has stopped responding to standard hormone treatment.
What could go wrong
This is a very early, small trial (10 people) focused on safety. The treatment may not shrink tumors or extend life, and there are risks of serious side effects from the cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••